When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by technological ambition, yet still grappling with many of the structural challenges that defined its beginnings, now compounded by the difficulty of positioning therapies within an ever more complex treatment landscape.Gleevec proved the power of targeting a genomic driver, but the healthcare system around it was far from ready. “We weren’t able to fulfill the promise as fast as we wanted to until that scaling happened,” Hinshaw told The BioCentury Show — a reminder that even today, precision medicines succeed or fail based not only on their biology but on the infrastructure that enables patients to access them.Hinshaw sat down with Executive Editor Selina Koch on The BioCentury Show to discuss what’s changed in precision oncology, what’s stayed the same, and how he’s applying those lessons to steer Fore’s BRAF-focused program.View full story: https://www.biocentury.com/article/657768#PrecisionOncology #BRAFAlterations #NGSTesting #MasterProtocol #TargetedTherapies00:00 – Introduction00:47 – Precision Medicine’s Evolution09:22 – Zeroing in on Subtypes17:59 – Fore’s BRAF Inhibitor26:38 – Fore’s Development Approach32:01 – Moving from Pharma to Biotech

Ver todos los episodios